Psychedelic research timeline
Personality Disorders: the psychedelic research timeline
Personality-disorder research is recent and mostly centred on BPD. Prospective cohorts and small psilocybin, MDMA and ketamine pilots now exist, but none yet amounts to a mature efficacy programme.
Milestones are editorially selected from Blossom’s research catalogue. Future markers are limited to important trials with dated public guidance and are shown as planned, not promised.
Hover any marker to preview its callout on the canvas, then click to pin it. Pinned is what stays open, fills this panel with the full context and links, and is what an export captures. Landmarks stay labelled on the canvas so the exported image reads on its own.
Download the artifact
Exports rasterise the live SVG, so whatever you have toggled is what you get.
Trait and cohort signals
2018 to 2021Emotion-regulation findings generate a treatment hypothesis.2018-11
Emotion dysregulation improves in an observational study
An observational study reports improved emotion dysregulation after ayahuasca in a community sample and people with borderline-like traits. It is not a treatment trial.
Diagnosis-specific pilots
2022 onwardsBPD and pathological-narcissism studies move the question into prospective trials.2022-09
The first BPD psilocybin trial opens
A Phase II study tests psilocybin in people with co-occurring major depression and borderline personality disorder.
2024-04
Prospective personality-disorder cohorts report
Two prospective cohorts report outcomes after psychedelic use in people with personality disorders. The naturalistic design cannot substitute for diagnosis-specific trials.
2024-08
MDMA is studied in pathological narcissism
A Phase I study begins testing MDMA-assisted therapy for pathological narcissism.
2025-02
A dedicated MDMA–BPD trial recruits
A Phase II study begins recruiting people with borderline personality disorder for MDMA treatment.
2025-11
A severe-BPD ketamine pilot is registered
BorderKET proposes a Phase II ketamine-infusion pilot for severe borderline personality disorder.
2026-04
An open-label BPD psilocybin study reports
An open-label study reports single-dose psilocybin in BPD with co-occurring MDD. Without a control group, the result remains preliminary.
Personality Disorders
Emotion regulation signals lead into the first diagnosis-specific pilots
Research Landscape
What the registered trials connected to Personality Disorders look like when you line them up. Counts come from Blossom’s trial records as of August 2026.
What's live right now, and what stopped?
SourcedRegistry status of all 6 Personality Disorders trials Blossom tracks. Orange marks trials recruiting or opening.
Don't read stopped trials as failures: trials end early for funding, recruitment, and strategy reasons too. Status is as last synced from the registry; some 'recruiting' trials may already have finished.
Publication Landscape
How the 19 papers Blossom links to Personality Disorders line up by year, compound and journal. This is the psychedelic-relevant literature in Blossom's records as of August 2026, not the condition's full medical literature.
How has Personality Disorders research grown?
SourcedTracked papers by publication year; 1 earlier paper published before 2012. Click a year for the running total.
Don't read as total output: only the 19 of 19 tracked papers with a recorded publication date are counted, and these are the psychedelic-relevant papers Blossom tracks, not a complete bibliography. The current year is still filling in.
Which compounds shape Personality Disorders?
SourcedTracked papers per compound. Orange marks the largest literature.
A paper studying several compounds counts once per compound, and placebo comparator arms are not shown. These are the psychedelic-relevant papers Blossom tracks.
Where is Personality Disorders research published?
SourcedTracked papers per journal. Orange marks the most-used journal.
Counts the journal recorded on each tracked paper; papers without a journal on file are omitted. Blossom tracks psychedelic-relevant papers rather than each journal's full catalogue.